高级检索

去唾液酸糖蛋白受体介导的肝肿瘤靶向载药系统研究进展

Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system

  • 摘要: 去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)是一种主要表达在肝窦状隙和基底外侧细胞表面的受体,它能专一性识别、结合并内吞末端具有半乳糖或乙酰氨基半乳糖残基的去唾液酸糖蛋白类物质。基于这一特性,ASGPR受体介导的肝肿瘤靶向治疗引起了研究者们的广泛关注。本文从糖基化前药、小分子纳米药物载体和糖基化基因复合物3个方面对近3年来该领域的最新研究进展进行综述。

     

    Abstract: Asialoglycoprotein receptor(ASGPR)is a receptor expressed mainly on the surface of liver sinusoidal and basolateral cells. It can exclusively identity, combine and clear desialylated glycoproteins with exposed non-reducing D-galactose(Gal)or nacetylgalactosamine(GalNAc)as end groups. Based on this characteristic, ASGPR-mediated targeted liver cancer therapy has drawn extensive attention. The present review details the latest research progress of this field in three aspects, glycosylated prodrug, small molecular nanocarriers, and glycosylated gene complex therapy system.

     

/

返回文章
返回